drugset / Trial / NCT04129099
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Phase 0
Unknown
18 enrolled
Hebei Yanda Ludaopei Hospital
Beijing Lu Daopei Hospital · collabGracell Biotechnology Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 18 subjects to receive GC022F therapy.
Timeline
- Start
- 2019-10-22
- Primary completion
- 2020-09
- Completion
- 2022-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC022F | Cell therapy | 60000 cells/kg | — |
| Subject | GC022F | Cell therapy | 150000 cells/kg | — |